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Abstract
Background: In heart failure patients, mean platelet volume (MPV) may reflect increased platelet activation or increased numbers of large, hyper-
aggregable platelets. B-type natriuretic peptide (BNP) concentration in blood is a sensitive and specific marker of heart failure, correlating with the 
severity and prognosis of illness, in patients presenting with acute dyspnea to the emergency department. This study evaluated the correlation 
between BNP concentration and MPV. 
Material and methods: Data were collected from 319 patients admitted to the emergency department of a cardiology hospital from January–July 
2014. EDTA blood samples drawn at admission were analyzed using automated hematology system, and BNP concentration was measured using a 
fluorescence immunoassay.
Results: The study included 190 patients with and 129 without acute heart failure (AHF). These groups had BNP concentration of 200-5000 ng/L 
and 5-98 ng/L, respectively. MPV levels were significantly higher in the AHF group (P < 0.001). BNP concentrations were positively correlated with 
MPV (r = 0.41, P < 0.001) and neutrophil / lymphocyte ratio (r = 0.38, P < 0.001).
Conclusion: Increased MPV values correlate with BNP concentration, an indicator of HF severity and clinical status, in patients with AHF admitted 
to the emergency department.
Key words: natriuretic peptide, brain; heart failure; platelet; mean platelet volume
Received: June 01, 2014 Accepted: November 29, 2014
Correlation between mean platelet volume and B-type natriuretic peptide 
concentration in emergency patients with heart failure
Yasemin U Budak*1, Kağan Huysal2, Hakan Demirci3
1Department of Clinical Laboratory, Yuksek Ihtisas Education and Research Hospital, Bursa, Turkey
2Department of Clinical Laboratory, Sevket Yilmaz Education and Research Hospital Bursa, Turkey




Heart failure (HF) is a condition in which the heart 
cannot pump sufficient oxygenated blood to meet 
the metabolic needs of body tissues (1). Although 
HF is a chronic disease, many patients experience 
acute symptoms, resulting in visits to the emer-
gency department (ED). Specific mechanisms lead-
ing to the development of acute heart failure 
(AHF) and the adverse outcomes associated with it 
remain unclear (2).
B-type natriuretic peptide (BNP) is a cardiac hor-
mone mainly secreted by cardiac myocytes in re-
sponse to ventricular volume expansion, pressure 
overload, and resultant increased wall tension (3). 
BNP concentration in blood is a sensitive and spe-
cific test for the identification of heart failure pa-
tients presenting with acute dyspnea to the emer-
gency department (1,4). Moreover, a BNP concen-
tration cutoff of 100 ng/L may be useful in distin-
guishing between cardiac and noncardiac causes 
of acute dyspnea (1,4). BNP concentrations also 
correlate with the severity and prognosis of illness 
(5).
Mean platelet volume (MPV), a routine measure of 
platelet size, may reflect increased platelet activa-
tion or increased numbers of large, hyperaggrega-
ble platelets (6). MPV levels were recently shown 
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to be increased in a number of disease states, in-
cluding myocardial infarction, unstable angina, 
and stroke (6,7). In addition elevated MPV was 
shown to be an independent risk factor associated 
with adverse cardiovascular events (8). Although 
recent studies have shown increased platelet acti-
vation in patients with heart failure (6), current evi-
dence is insufficient to support the hypothesis that 
platelet activation plays a direct role in the patho-
physiology of AHF. It is unclear whether increased 
platelet activity is related to a systemic imbalance 
or actually contributes to acute decompensation. 
To our knowledge, no study to date has evaluated 
the relationship between BNP concentrations and 
MPV in patients with AHF. This study therefore ret-
rospectively compared MPV levels and total 
thrombocyte counts in patients with and without 
AHF and the correlations of these factors with BNP, 
as well as with total white blood cell (WBC) count 
and neutrophil–lymphocyte (N/L) ratio as indica-
tors of systemic inflammation.
Materials and methods
Study design
This retrospective cohort study utilized hospital 
databases data from 319 patients admitted to the 
Emergency department of Bursa Yüksek İhtisas 
Research and Education Hospital from January to 
July 2014. The study was approved by the institu-
tional ethics committee of the hospital and was in 
compliance with the Helsinki Declaration. 
Subjects
Eligible patients were identified by a review of 
computer-based clinical records. Patients present-
ing with acute dyspnea as their main symptom 
and diagnosed with AHF according to European 
Society of Cardiology criteria were recruited (1). 
AHF as the leading diagnosis was the only inclu-
sion criterion (i.e., patients with acute coronary 
syndrome as the main diagnosis were not includ-
ed). All records were reviewed for confirmation of 
diagnosis, but none was excluded. 
The control group consisted of patients who pre-
sented with shortness of breath as their primary 
complaint and had no obvious traumatic or infec-
tious cause of dyspnea. Patients with severe renal 
disease (serum creatinine > 250 μmol/L) and pa-
tients in cardiogenic shock were excluded. 
Methods
EDTA blood samples (BD Vacutainer K2EDTA Plus 
plastic tubes; Becton Dickinson, Franklin Lakes, NJ, 
USA) were drawn from each patient at the time of 
admission and, according to the protocol of our 
emergency department, processed within 30 min-
utes of venipuncture. Samples were analyzed in an 
automated hematology analysis system (Coulter 
LH-780 hematology analyzer; Beckman Coulter 
Inc., Fullerton, CA, USA), which measures platelet 
size and platelet count using aperture-impedance 
technology. 
BNP concentrations were measured quantitatively 
using a fluorescence immunoassay with a single 
use device (Triage BNP Test; Biosite Inc., San Diego, 
CA) (8). The assay procedure involved the addition 
of several drops of an EDTA whole blood specimen 
to the sample port on the test device. A filter sepa-
rated the red blood cells from plasma and the 
plasma moved by capillary action into a reaction 
chamber to form a reaction mixture. After the in-
cubation period, the reaction mixture flowed 
through the device detection lane, with complex-
es of BNP and fluorescent antibody conjugates 
captured in a discrete zone of the detection lane. 
The concentration of BNP in the specimen was 
proportional to the fluorescence bound in the de-
tection lane and was quantified by the portable 
triage meter. The analytical characteristics of the 
system have been described previously; the in-
traassay and interassay coefficients of variation 
(CV%) of these kits were 8.8–11.6% and 9.9–12.2%, 
respectively. (9). BNP concentrations were meas-
ured within 30 minutes of venipuncture.
Statistical analysis
All statistical analyses were performed using SPSS 
10.0 (SPSS for Windows 10.0, Chicago, IL,USA). Sta-
tistically significant differences between parame-
ters with a Gaussian distribution were analyzed us-
ing Student’s t-tests and variables with a non-
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Gaussian distribution were compared using the 
Mann-Whitney U test. Normal distribution was as-
sessed using the Kolmogorov-Smirnov test. Corre-
lations were analyzed using Spearman’s correla-
tion test. Continuous variables are expressed as 
mean ± SD. All P values were two-sided, with a P 
value < 0.05 considered statistically significant.
Results
The study included 190 patients admitted to the 
emergency department with AHF and 129 without 
AHF. Demographic, clinical and laboratory param-
eters in the two groups are presented in Table 1. 
BNP concentrations in patients with and without 
AHF were 200-5000 ng/L and 5-98 ng/L, respec-
tively. MPV levels (P < 0.001), total neutrophil 
counts (P = 0.001) and neutrophile / lymphocyte 
ratios (P = 0.001) were significantly higher in the 
AHF than in the control group.
Data from the two groups were pooled to analyze 
the relationships between BNP and MPV, and with 
other hematological parameters (Table 2). BNP 
concentration was positively correlated with MPV 
(r = 0.41, P < 0.001) and PNL/L ratio (r = 0.38, P < 
0.001). 
There was a weak, although significant, negative 
correlation between MPV and platelet count (r = 
−0.41, P < 0.001).
Discussion
Although platelet numbers was similar in patients 
with and without AHF admitted to the emergency 
department, MPV was significantly higher in pa-
tients with AHF. Previous studies have assessed the 
prognostic role of MPV in patients with cardiovas-
cular diseases, although the mechanism responsi-
ble for increased platelet size in these patients re-
mains unclear (10). MPV appears to correlate more 
closely with platelet function than does platelet 
count alone (6). Large platelets that contain more 
dense granules are metabolically and enzymati-
cally more active than small platelets and have 
higher thrombotic potential. Platelet abnormali-
ties described in patients with chronic heart failure 




Age (years) (median, min-max) 71 (42-89) 67 (44-89)
Sex (F/N) 88/130 57/129
BNP (ng/L) 1547 ± 1214 31 ± 23
Total WBC (x 109 /L) 11.0 ± 8.2 9.3 ± 3.8
PNL/lymphocyte 6.2 ± 8.6 4.1 ± 6.8
Platelet (x 109 /L) 240 ± 78 245 ± 73
MPV (fL) 9.2 ± 1.1 8.3 ± 0.9
BNP - brain natriuretic peptide; WBC - white blood cell; PNL - 
polymorphonuclear neutrophils; MPV - mean platelet volume.
Table 1. Demographic and laboratory parameters in patients 
with and without AHF.
Parameter MPV PLT N/L ratio WBC
BNP
r 0.41 0.11 0.383 0.12
P < 0.001 0.84 < 0.001 0.02
MPV
r -0.41 0.20 0.07
P < 0.001 < 0.001 0.19
MPV - mean platelet volume, PLT – platelets; N/L ratio - 
neutrophil–lymphocyte ratio; WBC - white blood cell; BNP - 
brain natriuretic peptide.
Table 2. Correlation of BNP with biochemical parameters in all 
patients (N = 319).
(CHF) and AHF include increases in P-selectin ex-
pression, platelet aggregation, the expression of 
platelet-derived adhesion molecules and MPV (11-
15). Platelet activation markers are elevated re-
gardless of HF pathogenesis (14,16), with the sever-
ity of AHF correlated with the degree of platelet 
activation (17,18).
Activation of platelets can be evaluated by various 
techniques, including optical aggregometry, plate-
let function analysis using a PFA-100 system, plate-
let reactivity tests, platelet aggregate ratio meas-
urements, flow cytometry and thromboxane B2 
generation tests (19). The specificity and reproduc-
ibility of these assays are poor, limiting their clini-
cal use (19). In contrast, MPV is a simple marker 
that does not require advanced or expensive tech-
nology. 
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The activation of neurohormonal, inflammatory, 
and thrombotic pathways (20-22) has been found 
to be associated with enhanced platelet reactivity 
in patients with AHF (14,23-26). MPV has emerged 
as a relatively reliable marker of inflammation in 
patients with various diseases (27,28), with high 
MPV associated with low-grade inflammation. BNP 
concentration was positively correlated with MPV 
and PNL/L ratio, which indicates a direct role of 
platelet activation in the pathophysiology of AHF.
We also found that BNP concentration was posi-
tively correlated with PNL/L ratio. Leukocyte count 
has been reported to be a predictor of heart fail-
ure (29), as well as with the development of heart 
failure and one-year mortality rates in patients 
with MI (30). In patients with chronic HF, however, 
a low lymphocyte count or low percentage of lym-
phocytes has been associated with patient mortal-
ity (31,32).
This study had several limitations. One limitation 
was the use of EDTA as an anticoagulant, since 
EDTA increases nominal platelet volume. However, 
EDTA was found to increase MPV by only 3.4% af-
ter 60–120 minutes (33). Moreover, most studies 
using EDTA have avoided the period of rapid 
change by waiting 1–4 hours after collection be-
fore measuring MPV (33). Because our patients 
were seen in the emergency room, their blood cell 
counts were measured within 30 minutes after 
blood was taken.
The design of the present study is cross-sectional 
and thus cannot confirm a causal relationship. BNP 
concentration was assessed at a single point in 
time, and MPV is a nonspecific marker of platelet 
activation which can occur under various condi-
tions. Moreover, the relatively small sample size af-
fected the power of this study. Some of these pa-
tients were under antiplatelet therapy for their 
conditions which might affect our results. Howev-
er, there are reports that found no significant asso-
ciation between increased MPV and antiplatelet 
therapy (34,35).
Because this study was retrospective, we could not 
perform additional tests to determine the nature 
of the relationships among BNP, MPV and ventricu-
lar dysfunction in patients with HF. 
Conclusion
Our findings indicate that MPV values correlate 
with BNP concentration, an indicator of HF severi-
ty and clinical status, in patients with AHF admit-
ted to the emergency department. Further pro-
spective studies are needed to clarify these find-
ings. 
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